Secondary hyperparathyroidism - a common comorbid condition in patients with chronic renal insufficiency - is considered a consequence of critical determinants such as hypocalcemia, phosphate retention and reduced levels of calcitriol production. In this complex mechanism, the skeletal apparatus and the nonskeletal targets such as vascular and heart valves are often involved, thus explaining the increased risk of cardiovascular morbidity and mortality of uremic patients. In this review we will focus on the major role played by Calcitriol deficiency as a trigger of secondary hyperparathyroidism and the crucial need for obiquitous vitamin D receptor activation in order to have an optimal PTH control and to obtain a modulation between inhibitors and inducers of soft tissue calcification. This review will also elucidate the possible role of paricalcitol - a new vitamin D analog - in conditioning morbidity and mortality of patients on renal replacement therapy (RRT).
Management of secondary hyperparathyroidism in uremic patients : the role of the new vitamin D analogs / D. Brancaccio, M. Cozzolino, A. Galassi, G. Chiarelli, A. Butti, A. Bellasi, L. Rocca Rey, A. Volpi, A. Anelli, U. Zoni, M. Fusaro, C. Brambilla, E. Missaglia, C. Crovetto, M. Russo, C. Longhini, R. Provenzano, F. Incalcaterra, G. Cerasola, M. Li Vecchi, M. Gallieni. - In: JN. JOURNAL OF NEPHROLOGY. - ISSN 1121-8428. - 20:1(2007 Jan), pp. 3-9.
Management of secondary hyperparathyroidism in uremic patients : the role of the new vitamin D analogs
D. Brancaccio;M. Cozzolino;G. Chiarelli;A. Bellasi;L. Rocca Rey;M. Gallieni
2007
Abstract
Secondary hyperparathyroidism - a common comorbid condition in patients with chronic renal insufficiency - is considered a consequence of critical determinants such as hypocalcemia, phosphate retention and reduced levels of calcitriol production. In this complex mechanism, the skeletal apparatus and the nonskeletal targets such as vascular and heart valves are often involved, thus explaining the increased risk of cardiovascular morbidity and mortality of uremic patients. In this review we will focus on the major role played by Calcitriol deficiency as a trigger of secondary hyperparathyroidism and the crucial need for obiquitous vitamin D receptor activation in order to have an optimal PTH control and to obtain a modulation between inhibitors and inducers of soft tissue calcification. This review will also elucidate the possible role of paricalcitol - a new vitamin D analog - in conditioning morbidity and mortality of patients on renal replacement therapy (RRT).File | Dimensione | Formato | |
---|---|---|---|
Brancaccio et al - management of hyperPTH - JN 2007.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
322.91 kB
Formato
Adobe PDF
|
322.91 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.